Omnicell (OMCL) Tops Q1 EPS by 17c, Revenues Beat; Offers FY21 EPS/Revenues Mid-Point Outlook Above Consensus, Offers 2Q Revs. View Above Est.

Omnicell (NASDAQ: OMCL) reported Q1 EPS of $0.83, $0.17 better than the analyst estimate of $0.66. Revenue for the quarter came in at $251.84 million versus the consensus estimate of $246.7 million.

“We delivered an exceptionally strong first quarter, exceeding our first quarter guidance and achieving record revenue for the quarter,” said Randall Lipps, Chairman, President, Chief Executive Officer, and founder of Omnicell. “We continue to make tremendous progress advancing the vision of the autonomous pharmacy, and we continue to see robust and growing demand for our solutions as providers work to optimize and automate pharmacy workflows in response to the evolving healthcare landscape. Underscoring our momentum, we were pleased to increase the number of long-term, sole-source agreements with top 300 U.S. health systems. We are also very pleased with the strong reception of our Advanced Services portfolio during the quarter. We remain focused on supporting our healthcare systems partners on their journey to the Autonomous Pharmacy, driving growth and creating value for our shareholders, partners, and the communities we serve.”

GUIDANCE:

Omnicell sees Q2 2021 EPS of $0.80-$0.85, versus the consensus of $0.84. Omnicell sees Q2 2021 revenue of $265-270 million, versus the consensus of $263.54 million.

Omnicell sees FY2021 EPS of $3.50-$3.70, versus the consensus of $3.53. Omnicell sees FY2021 revenue of $1.09-1.15 billion, versus the consensus of $1.09 billion.

• For the second quarter of 2021, the Company expects total revenues to be between $265 million and $270 million. The Company expects product revenues to be between $192 million and $195 million, and service revenues to be between $73 million and $75 million. The Company expects second quarter 2021 non-GAAP EBITDA to be between $53 million and $56 million. The Company expects second quarter 2021 non-GAAP earnings to be between $0.80 and $0.85 per share.
• For the full year 2021, the Company expects product bookings to be between $1.090 billion and $1.150 billion. The Company expects total revenues to be between $1.085 billion and $1.105 billion. The Company expects product revenues to be between $770 million and $785 million, and service revenues to be between $315 million and $320 million. The Company expects 2021 non-GAAP EBITDA to be between $231 million and $243 million. The Company expects 2021 non-GAAP earnings to be between $3.50 and $3.70 per share.

For earnings history and earnings-related data on Omnicell (OMCL) click here.

You May Also Be Interested In

• Intuitive Surgiical (ISRG) beats earnings, revenue expectations in Q1
• United Bancshares, Inc. (UBOH) Reports Q1 EPS of $0.61
• Marten Transport (MRTN) Misses Q1 EPS by 2c